Obese patients study on remimazolam and alfentanil moves to recruiting for gastroscopy sedation — LiveFuture News
Open on LiveFuture.ai →

Obese patients study on remimazolam and alfentanil moves to recruiting for gastroscopy sedation

A recruiting clinical study is testing remimazolam besylate with alfentanil in obese patients during gastroscopy sedation, with ED90 as the main outcome and estimated primary completion in 2026-11.

A recruiting study is now looking at whether remimazolam besylate combined with alfentanil can better suppress the gastroscopic insertion response in obese patients. The registry entry is current as of 2026-11-09T00:00:00+00:00, and it matters because the focus is not just the procedure itself but how sedation is balanced during it.

The study is titled Determination of ED90 of Remimazolam Besylate Combined With Alfentanil for Gastroscopy Sedation in Obese Patients. It is listed as RECRUITING, with no results posted yet and an estimated primary completion date of 2026-11.

"The primary outcome is the ED90 (90% effective dose) of remimazolam besylate combined with alfentanil for suppressing the gastroscopic insertion response in obese patients."

How the study is set up

The trial is RANDOMIZED and uses two experimental arms: Group L (Low-dose alfentanil) and Group M (Moderate-dose alfentanil). The interventions are Alfentanil Hydrochloride Injection and Remimazolam Besylate for Injection, each linked to both groups.

Its main readout is the ED90, meaning the dose expected to work effectively for 90% of patients. The registry description says effective sedation is defined by a MOAA/S score ≤ 1 within 3 minutes after remimazolam administration, without coughing, swallowing or body movement during gastroscope insertion and within 1 minute after insertion.

"Effective sedation (suppression of gastroscopic insertion response) is defined as MOAA/S score ≤ 1 within 3 minutes after remimazolam administration, without coughing, swallowing or body movement during gastroscope insertion and within 1 minute after insertion."

What the dosing method suggests

The study uses a biased coin sequential allocation design, which means the next dose depends on what happened to the previous patient. If the previous patient has sedation failure, the remimazolam dose for the next patient goes up by 0.03 mg/kg.

If the previous patient achieves effective sedation, the next patient stays at the same dose with an 89% probability or drops by 0.03 mg/kg with an 11% probability. That makes the trial more of a dose-finding exercise than a finished answer, so the practical takeaway is still pending results.

"If the previous patient achieves effective sedation, the remimazolam dose for the next patient will maintain the same dose with an 89% probability or will be reduced by 0.03 mg/kg with an 11% probability according to the biased coin sequential allocation design."

Part of a broader obesity research cluster

This study also fits the active Obesity & Metabolic special event, which includes other obesity-related registry observations across treatment, measurement and safety topics. The linked event page is the clearest internal context for readers following this area.

Within that special event, the related signals span studies that are recruiting, not yet recruiting, or active not recruiting, including trials named for obesity, overweight, type 2 diabetes, food intake, metabolism, and gastrointestinal or ocular effects. Together, they show continued activity around obesity research, even though each study has its own separate question and status.

"This record describes a study and its registry status; study outcomes require posted results."